Short answer
CYTOKINETICS INC (CYTK) filed its Q2 2026 10-Q quarterly report on Aug 6, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $29M (down 57.1% year over year) with net income of −$199M.
Q2 2026 key financials · XBRL
- Revenue
- $29M
- −57.1% YoY · +47.9% QoQ
- Net income
- −$199M
- −47.9% YoY · +3.5% QoQ
- Operating margin
- -626.0%
- EPS (diluted)
- −$1.50
- −32.7% YoY · +10.2% QoQ
Source: XBRL data from the CYTOKINETICS INC (CYTK) Q2 2026 10-Q on SEC EDGAR. USD.
CYTOKINETICS INC Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q2 revenue $28.624M, down $38.145M YoY from $66.769M
- MYQORZO product revenue $25.334M, including U.S. $22.964M and Europe $2.370M
- Collaboration revenue $3.290M, up $0.874M YoY; license and milestone revenue $0 vs $64.353M
- Operating expenses $207.796M, up $29.521M YoY; R&D $97.807M, down $12.331M
- FDA lifted CK-089 partial clinical hold in Q2 2026; CEDAR-HCM enrollment completion expected Q3 2026
Risk Factors
- No material changes to risk factors since the March 31, 2026 Form 10-Q
- Carried-forward risks remain the company’s principal disclosed uncertainties
- No new regulatory, legal, or compliance risk identified this quarter
- No newly disclosed operational, competitive, market, liquidity, debt, currency, or concentration risk identified
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other CYTOKINETICS INC quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.